SignaCor
- Biotech or pharma, therapeutic R&D
SignaCor is a clinical stage, drug development company, spun-out from Queen’s University Belfast, dedicated to the treatment of cardiac disease.
At SignaCor, we are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM)—one that goes beyond symptom management to target the underlying disease pathology.
Address
BelfastUnited Kingdom
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}